Author:
Li Tao,Xie Qi,Fang Yang-Yang,Sun Yi,Wang Xiao Ming,Luo Zhu,Yan Gui-Ling,He Jian-Bo,Zheng Xiao-Qun
Abstract
AbstractBackgroundThe prognostic value of cytokeratin 19 fragment (CYFRA 21 − 1) and Ki67 in advanced non-small cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR) remains to be explored.MethodsIn this study, 983 primary NSCLC patients from January 2016 to December 2019 were retrospectively reviewed. Finally, 117 advanced NSCLC patients with wild-type EGFR and 37 patients with EGFR mutation were included and prognostic value of CYFRA 21 − 1 and Ki67 were also identified.ResultsThe patients age, smoking history and the Eastern Corporative Oncology Group (ECOG) performance scores were significantly different between CYFRA21-1 positive and negative groups (p < 0.05), while no significant differences were found in Ki67 high and low groups. The results of over survival (OS) demonstrated that patients with CYFRA21-1 positive had markedly shorter survival time than CYFRA21-1 negative (p < 0.001, For whole cohorts;p = 0.002, For wild-type EGFR). Besides, patients with wild-type EGFR also had shorter survival times than Ki67 high group. Moreover, In CYFRA 21 − 1 positive group, patients with Ki67 high had obviously shorter survival time compared to patients with Ki67 low (median: 24vs23.5 months;p = 0.048). However, Ki67 could not be used as an adverse risk factor for patients with EGFR mutation. Multivariate cox analysis showed that age (HR, 1.031; 95%CI, 1.003 ~ 1.006;p = 0.028), Histopathology (HR, 1.760; 95%CI,1.152 ~ 2.690;p = 0.009), CYFRA 21 − 1 (HR, 2.304; 95%CI,1.224 ~ 4.335;p = 0.01) and Ki67 (HR, 2.130; 95%CI,1.242 ~ 3.652;p = 0.006) served as independent prognostic risk factor for advanced NSCLC patients.ConclusionsOur finding indicated that CYFRA 21 − 1 was an independent prognostic factor for advanced NSCLC patients and Ki67 status could be a risk stratification marker for CYFRA 21 − 1 positive NSCLC patients with wild-type EGFR.
Funder
Natural Science Foundation of Zhejiang Province
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology